This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Regulation of subcellular distribution and oncogenic potential of nucleophosmin by plakoglobin
Oncogenesis Open Access 19 March 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Paqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254–266.
Bolli N, Nicoletti I, De Marco MF, Bigerna B, Pucciarini A, Mannucci R et al. Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. Cancer Res 2007; 67: 6230–6237.
Falini B, Bolli N, Liso A, Martelli MP, Manucci R, Pileri S et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia 2009; 23: 1731–1743.
Luo J, Qi C, Xu W, Kamel-Reid S, Brandwein J, Chang H . Cytoplasmic expression of nucleophosmin accuratety predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype. Am J Clin Pathol 2010; 133: 34–40.
Falini B, Sportoletti P, Martelli MP . Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. Curr Opin Oncol 2009; 21: 573–581.
Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909–1918.
Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman JW, Porwit A et al. Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Press-International Agency for Research on Cancer: Lyon, 2008, 120–123.
Schlenk RF, Döhner K, Kneba M, Götze K, Hartmann F, del Valle F et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 2009; 94: 54–60.
Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006; 107: 4011–4020.
Martelli MP, Manes N, Pettirossi V, Liso A, Pacini R, Mannucci R et al. Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: implications for the cell of origin of NPMc+AML. Leukemia 2008; 22: 195–198.
Otake Y, Soundarajan S, Sengupta TK, Kio EA, Smith JC, Pineda-Roman M et al. Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA. Blood 2007; 109: 3069–3075.
Paietta E . Expression of cell-surface antigens in acute promyelocytic leukaemia. Best Pract Best Res Clin Haematol 2003; 16: 369–385.
Hollink IH, Zwaan CM, Zimmermann M, Arentsen-Peters TC, Pieters R, Cloos J et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia 2009; 23: 262–270.
Martelli MP, Pettirossi V, Thiede C, Bonifacio E, Mezzasoma F, Cecchini D et al. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood 2010. E-pub ahead of print 15 July 2010; doi:10.1182/blood-2009-08-238899.
Acknowledgements
We thank all participating study centers for including their patients in the SAL trials. Generation of monoclonal antibodies anti-NPM1 (clones 322 and 376) was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC). This work was supported in part through BMBF grants no. 01GS0872 and 03WKBH2H to CT. The excellent skills of technicians Claudia Garten, Marika Karger, Sandra Kleiner; data manager Catrin Theuser; and statistician Michael Kramer are gratefully acknowledged. We further thank Michelle Meredyth-Stewart for her advice in preparing the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
BF has applied for a patent on the clinical use of NPM1 mutants. The other authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Oelschlaegel, U., Koch, S., Mohr, B. et al. Rapid flow cytometric detection of aberrant cytoplasmic localization of nucleophosmin (NPMc) indicating mutant NPM1 gene in acute myeloid leukemia. Leukemia 24, 1813–1816 (2010). https://doi.org/10.1038/leu.2010.178
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2010.178
This article is cited by
-
Hyperleucocytosis grading score and NPM1 gene mutation among patients with acute myeloid leukemia: Malaysian experience
Journal of Hematopathology (2020)
-
The concurrent use of N- and C-terminal antibodies anti-nucleophosmin 1 in immunofluorescence experiments allows for precise assessment of its subcellular localisation in acute myeloid leukaemia patients
Leukemia (2012)
-
Regulation of subcellular distribution and oncogenic potential of nucleophosmin by plakoglobin
Oncogenesis (2012)
-
Molecular-Based Classification of Acute Myeloid Leukemia and Its Role in Directing Rational Therapy
Molecular Diagnosis & Therapy (2012)
-
Reply to: ‘Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity’ by Kern et al.
Leukemia (2011)